We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PPD names Hill CEO

PPD names Hill CEO

September 20, 2011
CenterWatch Staff

CRO PPD, which has been the subject of takeover speculation since July, has named Raymond Hill its new chief executive officer, filling a position that was vacant since mid-May, according to a PharmaTimes report.

Hill comes to PPD from IMS Health, where he spent eight years and was most recently president of IMS Consulting Group. Hill oversaw a strategy of “aggressive organic and acquisition-based growth,” said PPD, helping to push up annual revenues five-fold over seven years and transform IMS from its data and market-research roots into a leader in pharmaceutical consulting.

PPD’s previous CEO, David Grange, retired May 18 after holding the post since mid-2009. Since then, Fred Eshelman has been filling in at the helm as executive chairman.

In July, PPD launched a review of its strategic planning and capital structure to see whether more value could be unlocked for shareholders. Eshelman insisted at the time that the company was “not engaged in any discussions around a combination with other clinical research providers.”

However, that did not rule out private equity interests, and in mid-August reports circulated that Carlyle Group was in talks, with the possibility of enlisting other private equity firms in a bid for PPD.  Speculation about Carlyle and PPD has cooled somewhat in recent weeks, though.

Before joining IMS Health, Hill was senior vice president for Acumen Sciences. He previously held a number of positions during an eight-year stint at A T Kearney, including global head of the pharmaceuticals and health care practice.

“With more than 20 years of experience in the life sciences arena, Ray brings keen strategic acumen as a proven leader who has grown global client services businesses in the pharmaceutical industry,” Eshelman said.

Global News Awards & Advancement

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing